EVIDENCE DESK / LONGEVITY ENDPOINTS
A Longer View of Longevity Research
Four compounds, four kinds of evidence: a calm guide to biomarkers, functional measures, clinical outcomes, and the claims that remain beyond the data.
NAD+
A cellular coenzyme with a clear biomarker story and a much less settled record for lasting human outcomes.
Read the NAD+ file »
MOTS-c
A mitochondria-derived signaling peptide whose functional promise still rests largely on cells, animals, and observational human data.
Read the MOTS-c file »
Tesamorelin
A growth-hormone-releasing analogue with human evidence for specific body-composition endpoints in a defined clinical population.
Read the tesamorelin file »
Semaglutide
A GLP-1 receptor agonist studied across weight, cardiovascular, and kidney outcomes, with a comparatively mature trial record.
Read the semaglutide file »The short version
Longevity research often begins with a reasonable idea and ends with a claim that travels farther than the evidence. A blood marker may move. A mouse may run longer. A trial participant may lose visceral fat or avoid a major medical event. These findings matter, but they are not interchangeable, and none automatically proves a longer human life.
Longevity Peptide is a reference desk for reading those steps in order. NAD+ begins with cellular energy and blood-level biomarkers. MOTS-c adds laboratory mechanisms and animal performance. Tesamorelin brings targeted human body-composition trials. Semaglutide reaches large clinical-outcome studies. The question throughout is simple: what did a study actually measure? That question separates a plausible pathway from a demonstrated benefit, and a demonstrated benefit from a lifespan claim. The aim is not to rank products. It is to make the evidence ladder visible.
Four files, one endpoint discipline
The compounds on this desk do not form a single drug class. NAD+ is an endogenous redox coenzyme and signaling substrate; its precursors are studied as ways to raise NAD+ availability. Reviews describe age-related changes in NAD+ biology while also emphasizing how limited and tissue-specific the human evidence remains [1][4]. MOTS-c is a mitochondria-encoded signaling peptide linked to metabolic stress responses, muscle biology, and nuclear gene regulation [10][12]. Tesamorelin acts through the growth-hormone-releasing hormone receptor and has trials centered on visceral and liver fat in adults with HIV-associated lipodystrophy [13][15]. Semaglutide is a GLP-1 receptor agonist with trials measuring weight, kidney events, and cardiovascular events [19][20][21].
Putting them together is useful precisely because their endpoint types differ. A biomarker shows that biology changed. A functional measure asks whether performance or daily capability changed. A surrogate outcome, such as visceral fat, may track with health risk but is not itself survival. A clinical outcome counts events that matter directly to patients. Lifespan is the hardest endpoint of all: it requires time, adequate follow-up, and a study designed to measure mortality rather than infer it.
What are research peptides?
A peptide is a short chain of amino acids, but “research peptide” is a setting, not a quality seal. Some peptides are investigational laboratory materials. Some become approved medicines after formal trials. Some substances discussed in peptide circles are not peptides at all: NAD+, for example, is a coenzyme and cellular metabolite. This hub keeps that distinction visible rather than forcing every member into one label.
Research may examine a molecular target, a cell response, an animal behavior, a blood marker, an imaging result, a functional test, or a clinical event. Each can answer a valid question. Trouble begins when a result is moved out of its proper category—for example, when improved treadmill performance in aged mice is retold as proof of human longevity. MOTS-c research illustrates both the interest and the limitation: animal work links the peptide to exercise capacity and muscle homeostasis, while human evidence in this corpus is observational rather than an efficacy trial [9][11].
How to read an endpoint
A useful reading order has four checks. First, identify the population: healthy adults, people with a specific condition, animals, or cultured cells. Second, name the intervention and comparator without turning the protocol into a recommendation. Third, locate the endpoint: blood concentration, imaging, physical function, symptoms, or clinical events. Fourth, ask how long the study followed participants and whether the endpoint was prespecified.
The same discipline prevents two opposite errors. It keeps an encouraging biomarker from being inflated into a lifespan promise, and it keeps a narrow but solid clinical result from being dismissed because it is not a universal anti-aging finding. On this desk, evidence earns its place on its own terms. The comparison matrix makes those terms explicit; the reference shelf provides the complete composed corpus behind every numbered citation.